Vtv Therapeutics
Late‑stage biopharma Vtv Therapeutics develops oral, small‑molecule treatments for diabetes and chronic disease, with lead Phase III candidate TTP399 (glucokinase activator) and a portfolio of PDE4 inhibitors and other disease‑specific agents.
Headquarters: United States (USA)
- Website: Visit Site 🔗
- Type: Corporation
Company Profile
- Sector: Hospitals and Health Care
- Industry: Medical and Diagnostic Laboratories
- Employees: 23
- HQ: High Point
Unlock the full potential.
Upgrade
Get access to Relative P/E Ratio Valuation Histogram.